PGP and neoplasm: The efficacy of the daily IDN 5390 was tested against two PTX- resistant ovarian human tumour xenografts, that is, the IGROV-1 (natural resistance, likely related to P-gp expression) and the INT-ACP/PTX (acquired resistance to both cisplatin and PTX).